Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

AIMS: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind, placebo-controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add-on to metformin plus sulphonylurea in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilding, J P H, Charpentier, G, Hollander, P, González-Gálvez, G, Mathieu, C, Vercruysse, F, Usiskin, K, Law, G, Black, S, Canovatchel, W, Meininger, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2013
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282288/
https://www.ncbi.nlm.nih.gov/pubmed/24118688
http://dx.doi.org/10.1111/ijcp.12322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282288/
https://www.ncbi.nlm.nih.gov/pubmed/24118688
http://dx.doi.org/10.1111/ijcp.12322

Ejemplares similares